AstraZeneca Pharma India

AstraZeneca Pharma India Limited reports a **30% revenue growth in Q2 FY 2026-27**, driven by strong performance in oncology, biopharmaceuticals, and rare disease therapies. The company’s total revenue for H1 2026-27 reaches **₹14,119 million**, up 30% year-over-year. Growth reflects consistent demand across its core therapy areas.

Nov 2026astrazeneca.inNews article

AstraZeneca Pharma India inaugurates a new corporate office in Mumbai to expand its operations in India. The move aligns with the company’s goal of advancing healthcare through scientific innovation and strengthens its local presence. The office marks a strategic step toward scaling research and development efforts in the region.

Oct 2026astrazeneca.inNews article

AstraZeneca Pharma India reports **30% revenue growth** in Q1 FY2026–27, reaching **INR 6,828 million** from operations. Growth stems from its core therapy areas—Oncology, Cardiovascular and Renal Medicine (CVRM), Research & Innovation (R&I), and Rare Diseases—highlighting its innovation-driven strategy. The company attributes performance to disciplined execution across its biopharmaceutical portfolio.

Aug 2026astrazeneca.inNews article

AstraZeneca Pharma India Ltd. secures CDSCO approval for **trastuzumab deruxtecan (100 mg/5 mL vial)** as an adjuvant treatment for adults with **HER2-positive early breast cancer** who exhibit residual invasive disease after neoadjuvant therapy. The drug, a lyophilized powder for infusion, targets patients with **IHC 3+ or ISH+ HER2 expression** who previously received trastuzumab (with or without pertuzumab) and taxane-based regimens. This expands the indication for the therapy in India’s oncology landscape.

Aug 2026astrazeneca.inNews article